Novartis India Ltd. Share Price & Stock Analysis

Novartis India Ltd. (BSE: 500672) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹3,910 Cr, it ranks #949 by market cap among the 6,197 Indian listed companies on FinBizNet, and #18 of 63 in Pharmaceuticals. At ₹1,722.40 (as of 16 Nov 2026), the share price is 33.5% below its 52-week high of ₹2,588.80 and 156.2% above its 52-week low of ₹672.25.

Key Metrics

Current Price₹1,722.40
Market Cap₹3,910 Cr
BSE Code500672
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio42.1
Return on Equity11.63%
Return on Assets6.13%
52-Week Range₹672.25 – ₹2,588.80
3-Month Price Change-1.8%
Beta (1Y)-0.02
Dividend Yield0.00%
HeadquartersMumbai, Maharashtra
Websitewww.novartis.in

Latest Quarterly Results — Q1 FY27

Revenue₹104 Cr
Net Profit₹32 Cr
Net Margin31.0%
EPS (Basic)₹13.05
Basisstandalone

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Novartis India Ltd. Quarterly Revenue and Profit Trend

Novartis India Ltd. reported revenue of ₹104 Cr in Q1 FY27, up 18.6% from ₹88 Cr in Q1 FY26 and up 14.6% from ₹91 Cr in Q4 FY26. It posted a net profit of ₹32 Cr for the quarter, against a net profit of ₹28 Cr in Q1 FY26 (up 16.6%). Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹84 Cr (Q4 FY25) to ₹104 Cr (Q1 FY27). The company was profitable in each of these 6 quarters.

QuarterRevenueNet ProfitNet Margin
Q1 FY27₹104 Cr₹32 Cr31.0%
Q4 FY26₹91 Cr₹25 Cr27.9%
Q3 FY26₹86 Cr₹16 Cr18.7%
Q2 FY26₹90 Cr₹24 Cr26.8%
Q1 FY26₹88 Cr₹28 Cr31.5%
Q4 FY25₹84 Cr₹29 Cr34.9%

Standalone figures (₹ crore, XBRL filings).

Shareholding and Delivery

Delivery averaged 50.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Novartis India Ltd.

Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. The company is a subsidiary of Novartis AG.

Products and Services

1. Pharmaceutical Business-This segment offers drugs and pharmaceutical products. 2. Generics-0 3. OTC-0 4. Animal Health-0

Business Segments

1. Pharmaceutical Business-100%

Novartis India Ltd. vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Novartis India Ltd.₹3,910 Cr42.111.63%₹104 Cr—

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Novartis India Ltd.?

Novartis India Ltd. is trading at ₹1,722.40, with a market capitalisation of ₹3,910 Cr.

Which sector does Novartis India Ltd. belong to?

Novartis India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Novartis India Ltd.?

Novartis India Ltd. has a P/E of 42.1 and a return on equity of 11.63%.

What is the stock symbol of Novartis India Ltd.?

Novartis India Ltd. is listed on the BSE under the scrip code 500672.

What were Novartis India Ltd.'s latest quarterly results?

In Q1 FY27, Novartis India Ltd. reported revenue of ₹104 Cr and net profit of ₹32 Cr, with basic EPS of ₹13.05 (standalone, parsed from the company's exchange filing).

How have Novartis India Ltd.'s revenue and profit changed over the past year?

Novartis India Ltd. reported revenue of ₹104 Cr in Q1 FY27, up 18.6% from ₹88 Cr in Q1 FY26 and up 14.6% from ₹91 Cr in Q4 FY26.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.